Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy
- PMID: 11571504
- DOI: 10.1038/sj.bmt.1703134
Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy
Abstract
Non-myeloablative regimens have been proven to allow engraftment following allogeneic stem cells transplantation (allo-SCT) with minimal procedure-related toxicity. Conventional allo-SCT may produce remissions in patients with relapsed and refractory lymphoid malignancies (LM) but these good results may be achieved at the cost of high treatment-related morbidity and mortality. Application of allo-SCT using less intensive regimens may temper the frequency of these complications, allowing a potent graft-versus-tumor effect (GVT). We present our data on 11 patients with LM receiving allo-SCT with a reduced regimen. Ten patients had received previous high-dose therapy, and were at high risk for toxicity, thus precluding the use of allo-SCT. A fludarabine and low-dose busulfan combination facilitated engraftment while exerting GVT. Hematological recovery was quick, and full donor T cell chimerism preceded acute GVHD. GVHD and infections were the major problems. Spontaneous acute GVHD occurred in eight patients (72%). Five patients (45%) achieved complete remission, and the GVT effect was closely associated with GVHD. These results support the concept that GVT is effective against LM in patients who have been heavily pretreated. Further studies are needed to investigate strategies to generate more specific alloreactive effects providing optimal GVT and an acceptable risk of GVHD and infections.
Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65. doi: 10.1053/bbmt.2003.50009. Biol Blood Marrow Transplant. 2003. PMID: 12720218 Clinical Trial.
-
Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies.Ann Hematol. 2003 Jan;82(1):1-13. doi: 10.1007/s00277-002-0586-9. Epub 2003 Jan 9. Ann Hematol. 2003. PMID: 12574957 Review.
-
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.Cancer. 2002 May 1;94(9):2409-15. doi: 10.1002/cncr.10491. Cancer. 2002. PMID: 12015766
-
Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.Chin Med J (Engl). 2007 Mar 20;120(6):463-8. Chin Med J (Engl). 2007. PMID: 17439737
Cited by
-
Large granular lymphocytosis after transplantation.Oncotarget. 2017 Sep 18;8(46):81697-81708. doi: 10.18632/oncotarget.21009. eCollection 2017 Oct 6. Oncotarget. 2017. PMID: 29113425 Free PMC article. Review.
-
Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.Biol Blood Marrow Transplant. 2012 Aug;18(8):1255-64. doi: 10.1016/j.bbmt.2011.12.581. Epub 2011 Dec 23. Biol Blood Marrow Transplant. 2012. PMID: 22198543 Free PMC article.
-
Busulfan-conditioned bone marrow transplantation results in high-level allogeneic chimerism in mice made tolerant by in utero hematopoietic cell transplantation.Exp Hematol. 2006 Mar;34(3):359-68. doi: 10.1016/j.exphem.2005.11.011. Exp Hematol. 2006. PMID: 16543070 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical